Product image of Olmesartan/Amlodipine Sandoz (Olmesartan Medoxomil, Amlodipine) supplied by GNH India

Olmesartan/Amlodipine Sandoz

Active Ingredient:
Olmesartan Medoxomil, Amlodipine
Origin:
EU

Olmesartan/Amlodipine Sandoz (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxil, the active ingredient in Olmesartan/Amlodipine Sandoz, is an angiotensin II receptor blocker presented as a fixed‑dose combination tablet for oral use. It treats hypertension, often in patients who require additional blood pressure control beyond monotherapy. GNH India supplies Olmesartan/Amlodipine Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH India supplies Olmesartan/Amlodipine Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Manufacturer / TM Owner

Sandoz N.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Olmesartan/Amlodipine Sandoz is indicated for the management of high blood pressure within the renin‑angiotensin‑aldosterone system pathway.

  • Hypertension: provides additive blood pressure reduction when monotherapy is insufficient.
  • Isolated systolic hypertension in the elderly: helps achieve target systolic pressures.
  • Hypertensive patients with concomitant calcium‑channel blocker need: offers convenient single‑pill therapy.
  • Patients requiring renin‑angiotensin blockade plus vasodilation: combines two mechanisms for better control.

How It Works

  • Olmesartan medoxil blocks the binding of angiotensin II to AT‑1 receptors, preventing vasoconstriction and aldosterone release. Amlodipine, a dihydropyridine calcium‑channel blocker, inhibits calcium influx into vascular smooth‑muscle cells, producing arterial dilation. The fixed‑dose combination therefore lowers systemic vascular resistance and reduces blood pressure through complementary actions on the renin‑angiotensin system and calcium‑mediated vascular tone.

Side Effects

Side effects reported with the combination reflect the profile of each component.

Common Side Effects

  • Peripheral edema: swelling of ankles or feet.
  • Headache: mild to moderate intensity.
  • Dizziness or light‑headedness: especially after standing.
  • Flushing: transient warmth sensation.
  • Fatigue: general tiredness.
  • Cough: rare, may be related to the ARB component.

Serious or Rare Side Effects

  • Angio‑edema: rapid swelling of lips, tongue or airway.
  • Severe hypotension: symptomatic low blood pressure.
  • Hepatic dysfunction: elevated liver enzymes.
  • Myocardial infarction: rare but reported.
  • Hyperkalemia: elevated potassium levels.
  • Acute kidney injury: sudden decline in renal function.

Precautions & Warnings

When prescribing Olmesartan/Amlodipine Sandoz, clinicians should consider several safety aspects.

  • Pregnancy: contraindicated due to risk of fetal toxicity.
  • Renal impairment: monitor kidney function and adjust therapy as needed.
  • Hepatic disease: use with caution; liver function should be assessed.
  • Electrolyte imbalance: watch for hyperkalemia, especially with concomitant potassium‑sparing agents.
  • Orthostatic hypotension: advise patients to rise slowly.
  • Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Olmesartan/Amlodipine Sandoz may interact with several drug classes.

Major Interactions (Avoid)

  • Dual renin‑angiotensin system blockade: combining with ACE inhibitors or other ARBs can increase risk of renal dysfunction and hyperkalemia.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise amlodipine levels, leading to excessive hypotension.

Moderate Interactions (Monitor Closely)

  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): can blunt antihypertensive effect and affect renal function.
  • Diuretics: may potentiate hypotensive response; monitor blood pressure.
  • Potassium‑rich supplements or salts: increase risk of hyperkalemia.
  • Lithium: may increase serum lithium concentrations.
  • Alcohol: additive blood‑pressure‑lowering effect; advise moderation.

Frequently Asked Questions

Olmesartan/Amlodipine Sandoz is a fixed‑dose combination tablet that treats hypertension. It combines an angiotensin‑II receptor blocker with a calcium‑channel blocker to provide more consistent blood‑pressure control than either component alone, especially in patients who need additional lowering of systolic and diastolic pressures.

Olmesartan medoxil blocks AT‑1 receptors, preventing angiotensin II‑mediated vasoconstriction and aldosterone release. This reduces peripheral resistance and fluid retention, helping to lower blood pressure as part of the renin‑angiotensin‑aldosterone system inhibition.

The dose is individualized by the prescribing clinician based on the patient’s blood‑pressure targets, renal function, and response to therapy. The prescriber determines the appropriate strength and titration schedule for each patient.

Both components are contraindicated in pregnancy because they can cause fetal toxicity, particularly renal and skeletal malformations. Limited data are available for breastfeeding; therefore, use is generally discouraged unless the benefit outweighs potential risk.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and import documentation.

The fixed‑dose combination offers convenience and may improve adherence by reducing pill burden. Pharmacologically, the blood‑pressure‑lowering effect is comparable to taking the two agents separately, but the single tablet simplifies dosing and may provide more consistent pharmacokinetic profiles.

Store the tablets at ambient temperature, below 25 °C, in the original container to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

The tablet is taken orally, usually once daily, with or without food. Patients should swallow the tablet whole with a glass of water and follow the dosing schedule prescribed by their healthcare professional.

Serious risks include angio‑edema, severe hypotension, acute kidney injury, hyper‑kalemia, and rare cases of myocardial infarction. Patients should seek immediate medical attention if they experience swelling of the face or throat, dizziness, fainting, or sudden changes in kidney function.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Olmesartan Medoxomil, Amlodipine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT